Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
(WorldNews Switzerland)

Net sales grew 5% (cc[1], +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD 239 million, (+113% cc) driven by continued uptake worldwide Oncology grew 10% (cc) driven by continued growth from Promacta/Revolade, Tafinlar + Mekinist and Jakavi, uptake of Kisqali and Kymriah and contribution from the AAA acquisition Core[1] operating income grew 7% (cc, +9% USD), driven by higher sales and improved gross margin, partly offset by growth investments Core EPS was USD 1.29 (+4% cc) as core operating income growth was partly offset by the discontinuation of income from the GSK consumer...